Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Response crawled date : 2021 - 09 - 13 save search
MREIC Underscores Responsiveness to Feedback from Stockholders Regarding Strategic Review Outcomes
Published: 2021-09-13 (Crawled : 21:00) - mreic.com
MNR | $20.09 -0.94% 0.0% 72K
|
Finance
|
| O: 0.81%
H: 2.03%
C: 1.5%
response
Monmouth Real Estate Underscores Responsiveness to Feedback from Stockholders Regarding Strategic Review Outcomes
Published: 2021-09-13 (Crawled : 21:00) - globenewswire.com
MNR | $20.09 -0.94% 0.0% 72K
|
Finance
|
| O: 0.81%
H: 2.03%
C: 1.5%
response
Longeveron Partners with Kinesiometrics to Create and Implement Cutting-Edge Smart Phone App to Measure Physical Responses to Cell Therapy
Published: 2021-09-13 (Crawled : 18:00) - biospace.com/
LGVN 4 d | $1.73 -4.95% -5.2% 300K
|
|
| O: 1.88%
H: 0.0%
C: -3.16%
therapy response
10 questions teams should be asking for faster incident response by Hannah Culver
Published: 2021-09-13 (Crawled : 17:00) - pagerduty.com
PD | News | $20.76 -1.38% 0.0% 1.1M
|
Technology Services
|
| O: 0.91%
H: 0.31%
C: -0.22%
skin response
Hawaiian Airlines Welcomes Guests to Travel Responsibly with New In-flight Video
Published: 2021-09-13 (Crawled : 16:00) - prnewswire.com
HA | $12.42 -3.72% -3.86% 1.5M
|
Transportation
|
| O: 0.82%
H: 4.96%
C: 4.04%
travel response
Adaptimmune Announces Clinical Responses across Five Solid Tumor Indications with an Overall Response Rate of 36% and Promising Early Durability from its Next-Generation SURPASS Trial
Published: 2021-09-13 (Crawled : 14:00) - biospace.com/
ADAP | $1.085 -4.83% -5.07% 780K
|
Health Technology
|
| O: 9.12%
H: 0.29%
C: -14.22%
trial solid tumors response
ImmunityBio Announces Positive Durable Responses in BCG Unresponsive Bladder Cancer Patients with a Complete Response Rate of 72%, Median Duration of Complete Response of 19.9 Months, and 85% Remaining Cystectomy-free in Phase 2/3 Trial
Published: 2021-09-13 (Crawled : 13:00) - nantkwest.com
IBRX | $4.815 -12.3% -14.02% 7.9M
|
Manufacturing
|
| O: 0.81%
H: 3.11%
C: -2.01%
media phase 2 phase 2/3 positive cancer trial response bladder
aTyr Pharma Announces Positive Data from Phase 1b/2a Clinical Trial Demonstrating Consistent Dose Response for ATYR1923 in Pulmonary Sarcoidosis
Published: 2021-09-13 (Crawled : 12:00) - globenewswire.com
LIFE | $1.595 -1.54% -1.57% 290K
|
Health Technology
|
| O: 14.96%
H: 47.46%
C: 45.24%
phase 1 positive trial phase 1b phase 2b response
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.